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Abstract    8 
It is nearly 60 years since the identification of the oestrogen hormone receptor (ER) in breast 9 
cancer, a discovery that radically transformed the clinical management of the disease. 10 
Hormonal therapy with anti-oestrogens (Tamoxifen and Aromatase inhibitors) antagonise ER 11 
function and became the mainstay treatment until today. Around 70% of breast tumours are 12 
classified as oestrogen dependent, yet the mechanism of action of other hormones in breast 13 
cancer growth both independently and interacting with ER as well as their targeted therapies 14 
have yet to find a place in the clinic. In this article, I critically review the scientific literature 15 
for the period 1960-2016, examine the rise and persistence of the oestrogen hypothesis as 16 
well as the neglect of alternative hormonal explanations. By using Pierre Bourdieu’s concepts 17 
of the scientific field alongside feminist science scholars to explore the impact of gendered 18 
assumptions on science, the analysis provides insight into the dominant role of the oestrogen 19 
hypothesis and the struggles for legitimation of different alternative perspectives. I consider 20 
these alternative approaches as “internal” struggles for scientific authority, which are in turn, 21 
socially determined by “external” gender values that reinforce a binary arrangement of 22 
male/female bodies based on fixed molecular hormonal traits.    23 
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Introduction 4 
Contemporary hormone therapy for breast cancer is considered as “one of the most 5 
remarkable stories in cancer therapy” (Geisler and Lønning, 2005: 2809). Part of this 6 
enthusiasm can be explained by its role as adjuvant therapy after surgery (to prevent 7 
recurrence), and to extend years of life in advanced stages of the disease. About 70% of 8 
breast cancers are considered to be oestrogen hormone dependant, which places this therapy 9 
at the centre of breast cancer clinical management today. Despite its relevance in cancer 10 
treatment, its conspicuous association with the gendered hormonal body, and a large body of 11 
literature dealing with ‘sex hormones’, social scientists and feminist scholars alike have paid 12 
little attention to how this particular field of cancer treatment has evolved. To begin to fill 13 
this gap, in this article I conduct a critical review of the scientific literature related to 14 
hormones and breast cancer and explore the main contributions that emerged since the 15 
discovery of the oestrogen receptors in the 1960s to 2016. My focus is on how the field 16 
developed from a particular oestrogen hypothesis (oestrogen receptors) to explain tumour 17 
growth, and how this perspective came to dominate until the present. I consider alternative 18 
hypotheses that raised attention to other hormones and their mechanism of action both 19 
independently and in relation to oestrogens.  20 
To help explain the trajectory of these developments, I use some of the sociological 21 
categories of Pierre Bourdieu, as “thinking tools” rather than a prescriptive construct as 22 
proposed by Brubaker (1993), alongside feminist science studies, in particular those that have 23 
proposed a return to the technological and scientific matter (atoms, bones, molecules, to name 24 
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a few examples) to simultaneously integrate the material, social, and cultural environment 1 
through different frameworks (Barad, 2007; Birke, 2000; Fausto-Sterling, 2017; Roy, 2018).  2 
Bourdieu’s definition of the scientific field as composed by “forces whose structure is 3 
defined by the continuous distribution of the specific capital possessed, at the given moment, 4 
by various agents or institutions” and characterised by struggles, where agents and 5 
institutions compete for scientific capital (1991: 6–7) will guide my analysis of the specific 6 
subfield, i.e. the hormone therapy field (HTF).  Bourdieu’s theoretical framework and the use 7 
of its key concepts (i.e. field, capital, habitus) have allowed social scientists to extend, test, 8 
and re-interpret these constructs in different areas of research. The integration of Bourdieu’s 9 
field theory has however been considered problematic due to his lack of empirical 10 
application, as well as his emphasis on the autonomy of the scientific field from external 11 
determinants (Camic, 2011; Mathieu and Kleinman, 2011). Bourdieu’s notions of gender, on 12 
the other hand, have been debated by feminist and gender scholars who have developed an 13 
overarching perception that gender has not been systematically analysed, nor in the social 14 
order – as hierarchical relations/binary oppositions – or in the different spaces of social life 15 
(fields). “Where gender order appears to be universally reproduced on the one hand, gender 16 
as an organizing principle remains secondary on the other” (McCall, 1992: 851).  17 
These criticisms in particular seem both to point to Bourdieu’s lack of simultaneous attention 18 
to what he described as a two-fold relationship in the production of scientific knowledge 19 
(Bourdieu, 1990, 298): the “external” factors to which he referred as “the larger social 20 
space”, the “social order”, the “general economic and social conditions”, and on the other 21 
hand, the “internal” factors operating in the scientific field as an “autonomous world 22 
endowed with its own rules of functioning”. The latter has constituted the predominant focus 23 
of Bourdieu’s analysis of science, as Camic has argued, “it is to the scientific field that he 24 
regularly turns” (Camic, 2011, 277). In this sense, despite the proposition of the existence of 25 
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a “relative autonomy” of the scientific field, rather, Bourdieu’s concentration on the internal 1 
dynamics of the field endowed it with absolute autonomy as he provided very few clues and 2 
little detail on how external forces interact, affect or determine the internal ones. From the 3 
perspective of gender, MacCall observes, “the social order is perhaps the most elusive of 4 
Bourdieu's concepts” (1992: 839). It is assumed to become internalised as unconscious 5 
scientific habitus including those of the “tacit laws of governing the field” (Bourdieu cited in 6 
Brubaker, 1993: 230).  7 
Using field analysis to understand the cancer research therapeutic field, Stewart and Rauch 8 
(2016) highlight its heteronomous nature, and assert that “It is by no means a ‘pure’ zone of 9 
disinterested scholarly activity and scientific discovery” (2016:481). In this review of the 10 
literature, I inquire into the autonomy of the HTF in relation to external forces, primarily the 11 
relevance of gender for the construction of scientific knowledge and its implications in other 12 
sub-fields such as clinical medicine and the pharmaceutical industry. The latter also intersects 13 
with strong economic pressures influencing research funding, marketization of anti-cancer 14 
drugs, and their access in the healthcare system. The agents of the HTF are laboratory 15 
scientists from different disciplines: chemists, molecular biologists and geneticists, cell-16 
biologists, pathologists, pharmacologists as well as medical researchers who tested the new 17 
drugs in the clinic. I propose that the HTF’s interactions with the clinic (drug availability, 18 
clinical research) can act as a hinge between the “social order” or “external factors” and the 19 
internal dynamics of the HTF in their delineation of experimental research and scientific 20 
hypothesis, and in the struggle for scientific authority (social capital).  21 
For the social order, I focus on broader societal gender norms that have long permeated the 22 
scientific and medical understandings of the hormonal body as sexually specific: oestrogens 23 
in women, androgens in men. Feminist biologists such as Fausto-Sterling have reasoned that, 24 
“our beliefs about gender aﬀect what kinds of knowledge scientists produce about sex in the 25 
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ﬁrst place” (2000: 3). Yet to take account of these gender-science entanglements and to 1 
elaborate an alternative narrative other than “critique” of biological knowledge, implies a 2 
disposition to learn (new) discipline-specific ways of knowing and producing scientific facts, 3 
to reach out to the phenomena that one seeks to discern, in my case the HTF. In this sense, 4 
there is no method for analysing the biological matter, and here my engagement with the HTF 5 
is indirect (I am not a specialist trained in this field), but neither this is an attempt to read 6 
biology against the social. It is rather an attentive reading of scientists’ elaborations on 7 
tumour biology (and their struggles for social capital), with a focus on “what gets excluded 8 
and how those exclusions matter” (Barad, 2007: 30). 9 
As I will argue in this article, hormonal therapy for breast cancer  ̶  from key scientific 10 
explanations of tumour growth to mainstream drugs and clinical guidelines  ̶  has been 11 
persistently receptive towards the role of oestrogens (the female ‘sex hormone’), but has 12 
remained reluctant in recognising the action of other hormones despite more than 40 years 13 
evidencing their role on the disease.    14 
 15 
Methods 16 
I analyse the period 1960-2016 and concentrate on the key research lines, approaches or 17 
contributions to the HTF. Given the considerable amount of existing literature on this topic 18 
and period, the following search strategy was designed: firstly, searches were conducted 19 
electronically on the Pub Med database for review articles only (available from the 1980s), 20 
with added filters for title, English language and the time frame specified above. Search terms 21 
included: “o-estrogen/ progesterone/ androgen receptor AND breast cancer”. After checking 22 
for duplication, the results were as follows: single hormones (o-estrogen 220; progesterone 23 
17; androgen 25; and o-estrogen and progesterone: 14). This was further screened for expert 24 
reviews on the status of each hormone receptor and a sample of at least one article per 25 
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decade. For the latter, simple historical accounts and reviews of similar content were 1 
excluded, unless they explained the development of a new approach which was not described 2 
elsewhere in the literature. This allowed for the initial identification of relevant articles. 3 
Secondly, snowballing strategy (reference tracking) was used based on the significance given 4 
by laboratory scientists and medical researchers to key papers (which informed the basis for 5 
their hypothesis, experiments and clinical trials), and by further scanning using the 6 
bibliographies of relevant papers I was already aware of drawing on my previous research in 7 
hormones and breast cancer (Eraso, 2014, 2018). 8 
In all, I analysed 19 expert reviews in a variety of specialised journals, and 56 original 9 
research articles (oestrogen 19; progesterone 13; androgen 19; and combination of hormones 10 
5). Results are presented according to five main research lines in hormonal therapy. In order 11 
to reflect critically on the literature, I applied Bourdieu’s notions of the scientific field 12 
alongside feminist science scholars to explore the impact of gendered assumptions on the 13 
HTF. 14 
The oestrogen hypothesis 15 
In 1962, chemists Elwood Jensen and Herbert Jacobson of the University of Chicago 16 
identified what is now widely known as oestrogen receptor (ER), an oestrogen-binding 17 
protein located in tissues (uterus, vagina, and breast) to which circulating oestrogens interact 18 
causing cell division and proliferation (Jensen and Jacobsen, 1962). For their experiment, the 19 
researchers administered oestrogen to immature female rats, for which they developed a 20 
novel technique, a radioactive oestrogen tracer, which fitted into the small physiologic dose 21 
of oestrogen that it is commonly injected into rats. The study showed that the radioactive 22 
oestrogen was retained in the uterus and vagina, whilst in other organs was quickly degraded; 23 
and that there was an oestrogen binding protein to which the oestrogen hormone binds 24 
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producing uterine growth. Subsequent studies (Noteboom and Gorsky,1965; Shyamala and 1 
Gorsky, 1969) confirmed the protein structure of the receptor and its location in the nucleus, 2 
where it interacted with DNA regulating gene expression. Also, O’Malley’s team elucidated 3 
the mechanism of nuclear hormone receptors as regulators of nuclear tRNAs producing new 4 
protein synthesis. Steroid hormones binding to their receptors thus regulated the transcription 5 
of genes through complex pathways (Chan et al,1973; O’Malley and McGuire, 1968).    6 
Jensen’s discovery was a milestone at the time, since it opened up the possibility to identify 7 
which types of cancer could be responsive to hormonal treatment and which ones could not 8 
(Jensen et al, 1971), thus reducing the number of unnecessary invasive procedures such as 9 
ovariectomy, adrenalectomy, and hypophysectomy, which were known as the main 10 
oestrogen-producing glands. More importantly, it also led to a paradigm shift: instead of 11 
focusing on blocking the source of oestrogen, it paved the way for the development of new 12 
therapies that would block the hormone receptor.  13 
Up until 1962, all studies were concentrated on elucidating the action of oestrogens on their 14 
biosynthesis, their enzyme-induced metabolic action on tissues. Confidence in the action of 15 
oestrogens, given their ability to alter processes of different kinds, was formidable and easily 16 
adopted as an experimental scientific hypothesisi. Animal experiments with oestrogen 17 
administration rendered immediate, direct observations of palpable organ-changes, as 18 
opposed to the mediated way of observing cell phenomena through the microscope, thus 19 
strengthening the already extreme confidence in the action of oestrogens as substances 20 
(whether exogenous or endogenous) in the development of organs, tissues and physiological 21 
action in the female body, including the mitotic action (cells that multiply) associated with 22 
cancerous processes. Jensen’s study, however, demonstrated that the oestrogen hormone did 23 
not experience any chemical change in the process, it was the ER located in the nucleus of the 24 
cells in tissues that through complex mechanisms regulated the activity of different genes.  25 
8 
 
Jensen's “alternative approach”, a term he later used to explain his novel hypothesis, left, in 1 
his words, the scientific community “surprised” (Jensen et al, 2010: 153). He summed it up 2 
with the following statement: study “not what the hormone does to the tissue but what the 3 
tissue does to the hormone” (Jensen et al, 1966: 133). A focus that displaced the role of the 4 
otherwise perceived mighty action of the ‘sex hormone’ to a position of dependence on the 5 
existence of receptors in tissue. Unlike ‘sex hormones’, tissue − in the scientific language and 6 
metaphorical associations used to describe bodily parts at the time − had no sex.  We know, 7 
however, that oestrogens did not become degendered, and that hormones’ action or 8 
“messaging” as Celia Roberts has proposed, “is received and responded to within bio-social 9 
(as opposed to purely biological) systems or worlds” (2007: 22-23).  But decoupling its 10 
biological action in breast cancer from an ontological position to one of dependence and 11 
subordination opened up a whole new approach to study complex interactions. Some of the 12 
implications of these new hypothesis started with the identification of ER properties in 13 
human tissue (McGuire and Delagarza, 1973) and will be explored later in this review.  14 
In the next section, I examine the HTF from the perspective of clinical researchers and the 15 
pharmaceutical industry as they revealed in the clinic a much more complicated use of 16 
therapeutic agents: one that exposed the underlying gender norms that limited, at the time, the 17 
autonomy of the HTF.  18 
Androgens in the clinic 19 
Hormone therapy was informed in the 1960s by clinical research going back to the end of the 20 
1930s that reported on the use of oestrogens, progesterone and testosterone. The first clinical 21 
use of testosterone to treat breast cancer patients started in 1938 when a gynaecologist, Alfred 22 
Loeser, reported that “testosterone had an inhibiting effect” (Loeser, 1940: 481). Hormone 23 
therapy was informed by the notion of ‘balance’, which implied tinkering the dosage of the 24 
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antagonist or ‘contra-sexual’ hormone to level out the quantities of hormones circulating in 1 
the body. As the use of testosterone propionate and oestrogens expanded in the clinic, 2 
standardisation of their use was sought by the Council on Pharmacy and Chemistry (1947-3 
1951), which compared the efficacy of both drugs through a series of clinical-therapeutic 4 
evaluations. Objective responses (tumour reduction, metastasis improvements) and subjective 5 
responses (sense of wellbeing, pain relief) were evaluated, but in the case of testosterone, the 6 
concern to establish a dosage aimed to balancing something else: notions of gender. The 7 
masculinising side effects that testosterone produced in women, namely hirsutism, deepening 8 
of the voice, acne, enlargement of the clitoris, and increased libido, challenged its value as an 9 
anti-tumour agent and led to the determination of an optimal dosage that would meet instead 10 
three factors, objective and subjective improvements and low “masculinizing action” 11 
(Council of Pharmacy, 1951: 475). During this period, female virilisation became a highly 12 
debated topic amongst clinical researchers in the United States, and those who deemed it 13 
negatively succeed in fuelling a ‘narrative of abandonment’: most oncologists today concur 14 
with this view when observing that “androgens have antitumor effects but were abandoned 15 
from breast cancer therapy due to their side effects” (Geisler and Lønning, 2005: 2810). 16 
In the decades that followed, experimental clinical research with testosterone, however, did 17 
not decline; on the contrary, it was widely stimulated by the pharmaceutical industry that 18 
began to focus on testosterone derivatives with a gender objective to which it presented 19 
straightforwardly: the development of a substance providing “efficacy without virilization” 20 
(Goldemberg, 1973: 1268). The first drug to appear on the market was Fluoximesterone 21 
(Halotestin, 1959), a potent anabolic-androgenic steroid whose patent stated, “diminution or 22 
elimination of androgenic activity without loss of other properties exhibited by ‘androgens’ ” 23 
(Nathan et al, 1959: 1395). During the 1960s and 1970s a series of randomized clinical trials 24 
were developed to analyse these new compounds and the research group that coordinated 25 
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them was the Cooperative Breast Cancer Group (CBCG), sponsored by the National 1 
Institutes of Health. The CBCG attempted to overcome the perceived discrepancies between 2 
“objective”, “subjective” and “masculinizing action”, introducing the criteria that 3 
characterised the randomised clinical trial (RCT). It developed a single “objective” criteria to 4 
test the efficacy of the drugs, which included randomisation, external evaluators and an 5 
indicator for disease regression (Goldenberg et al, 1973: 1267). According to the strict CBCG 6 
protocol, a patient was considered to have an “objective” regression while receiving 7 
treatment if more than 50% of all lesions decreased in size while all other lesions remained 8 
static; or more than 50% of non-bony lesions decreased in size while all bone lesions 9 
remained static and without the appearance of new lesions during therapy (Goldenberg et al, 10 
1973: 1267). The women selected for hormone therapy were postmenopausal, and their 11 
disease was advanced enough to benefit from surgical and radiotherapeutic treatment. A 12 
summary of the clinical trials of the CBCG in the 1960s and 1970s, indicated: similar 13 
regression rates (21.5%) for both Stilbestrol [oestrogen] and testosterone propionate 14 
(Goldenberg, 1964; Segaloff, 1966); similar efficacy for testosterone propionate and new 15 
anabolic androgens, and for the latter a response rate of around 28% (Goldemberg et al, 16 
1973; Talley et al, 1973). This clear effort in the US context to restrict and prioritize 17 
“objective” improvements over “subjective” ones gave androgens a potential role in the 18 
clinic. In particular, for clinicians who saw in androgens an effective therapy whose benefits 19 
should be safeguarded by scientific protocols rather than professionals’ preferences or 20 
opinions about their undesirable side effects (masculinizing or virilising). However, it was the 21 
subjective perception of clinicians and gynaecologists and their preferences in the use of 22 
oestrogens over androgens which played an over-determining factor behind the use of the 23 
drug. This is clearly illustrated by a member of the CBCG group, who thus advocated for the 24 
use of anabolic-androgenic steroids, “In my view, the virilisation produced by testosterone 25 
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propionate makes it a cruel treatment even though it is effective. Since I consider 1 
androgenicity sufficiently undesirable to contraindicate using an effective agent [anabolic-2 
androgenic steroid],….” (Gordan, 1969: 41). The development of ‘objective’ measures for 3 
the use of androgens thus became for advocates within the CBCG a way to preserve their use 4 
in the clinic, in a context of medical criticism and anxiety about the gender disorders 5 
propitiated by the drug. It is worth considering here that the medical literature of the time 6 
only referred to the subjective opinions of clinicians in relation to how much virilization 7 
could be tolerated in their patients (usually symptoms of hirsutism, a hoarse voice, or 8 
increased libido) and that women’s decisions in relation to ‘androgenicity’ were never 9 
collected as data or reason for discontinuation.  10 
As for the various non-virilising androgen derivatives of the pharmaceutical industry that 11 
were evaluated by the CBCG in the 1960s and 1970s, in many cases with positive results, it 12 
can be observed in some medical reports, the implicit questioning of the overestimation of 13 
oestrogens over androgens. In 1975, one of the CBCG's managers, Dr Albert Segaloff, 14 
reflected, “The largest class of hormones which have been administered are estrogens” 15 
(Segaloff, 1975: 133). He also drew attention to the fact that there was only one compound 16 
(diethylstilbestrol) which from the 1950s became the “cornerstone” for the treatment of 17 
advanced breast cancer. “As opposed to the success in developing androgens with lesser 18 
androgenic activity still active against breast cancer, we are not aware of any such estrogen 19 
derivatives” (Segaloff 1975: 133) In addition, he questioned the lack of clinical trials on the 20 
appropriate dose of oestrogens to be administered, despite oestrogens’ known toxicity 21 
(nausea, vaginal bleeding, breast soreness, fluid retention, stress incontinence).  22 
The advent of an anti-oestrogen drug (Tamoxifen), which acts on the hormone receptor 23 
discovered by Jensen, that was thought to have little toxicity at the time, gave the use of 24 
androgens the final blow. As stated by an American oncologist:  25 
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The studies of the Cooperative Breast Cancer Group did not succeed in their 1 
quest for the “super” androgen. Although androgens are easy to administer, 2 
relatively inexpensive, and have potent anabolic effects, their virilizing 3 
properties alarmed many patients and oncologists. Since the advent of the 4 
antiestrogens […] androgens have fallen into disfavor. […]  The benefits of 5 
male hormones are outweighed by their alarming virilizing effects (Kaufman, 6 
1981: 196; 198 – my emphasis). 7 
 8 
Tackling oestrogen action and synthesis: Anti-oestrogens and aromatase inhibitors 9 
Anti-oestrogen (Tamoxifen): In the mid-1970s the “accidental discovery” of an anti-oestrogen 10 
drug marked future developments in the clinical management of hormone-dependant tumours 11 
and it further legitimised the persistence of the oestrogen hypothesis, granting it star billing. 12 
Tamoxifen (ICI 46,474) became the first cancer target drug due to its ability to block or 13 
inhibit ER in mammary cells. The history of Tamoxifen counts it as a random discovery as it 14 
first emerged as a contraceptive drug (ICI 46,474) at the Imperial Chemical Industries 15 
Pharmaceuticals Division, UK.  As an anti-oestrogen for post coital action - the “morning 16 
after pill” - ICI 46,474 was soon found to produce the opposite effect (stimulated ovulation) 17 
so pharmaceutical interest in this area was quickly abandoned. However, its conversion into a 18 
cancer drug was promoted by the British Pharmacologist, Craig Jordan, who between 1972-4 19 
developed a research strategy at the Worcester Foundation for Experimental Biology 20 
(WFEB), in Massachusetts, with the aim of assessing the potential action of anti-oestrogens 21 
in tumours with positive ER, as identified by Jensen.  22 
The first clinical study comparing the effectiveness of ICI-46,474 with androgens and 23 
oestrogens for women with metastatic breast cancer in the UK, gave similar results for the 24 
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three drugs, with the advantage of ICI 46,474 having “lower toxicity” in comparison with 1 
oestrogens, whilst “the virilizing effect of androgens has not been seen” (Cole et al, 1971: 2 
274).  3 
Jordan, however, developed (and tested in rats) another hypothesis, which implied the use of 4 
Tamoxifen to prevent recurrence, i.e. not for metastatic/palliative treatment only, but to all 5 
ER+ postmenopausal women and for a longer period (more than one year) of medication-6 
taking, an approach he synthesised as “longer was going to be better” at controlling 7 
recurrence: Between 1977-78 he presented results demonstrating that, long term, Tamoxifen 8 
was a more effective adjuvant therapy (Jordan, 1978). Jordan’s promising laboratory results 9 
for post-menopausal and pre-menopausal women (Jordan and Allen, 1980) were quickly 10 
trialled and extended to the clinic. In fact, like any adjuvant hormonal treatment, the role of 11 
Tamoxifen was to prevent recurrence of the disease and to extend years of survival in cancer 12 
patients. By 1985 the National Cancer Institute Consensus Conference proposed that 13 
Tamoxifen should be the standard treatment for postmenopausal women with ER positive 14 
tumour and positive axillary nodes (NIH, 1985).  15 
Another hypothesis Jordan developed at the WFEB was that Tamoxifen might act as a 16 
chemoprevention for breast cancer (Jordan, 1976). The finding that contralateral breast 17 
cancer was reduced with the administration of Tamoxifen as adjuvant therapy prompted the 18 
testing of the drug as a chemopreventive agent. Between 1992-98 Tamoxifen was trialled in 19 
the National Surgical Adjuvant Breast and Bowel Project (NSABP) which enrolled 13,800 20 
asymptomatic American women (without cancer) but at high-risk of contracting the disease, 21 
and obtained a 50% reduction in cancer incidence in the Tamoxifen-treated group (Fisher et 22 
al, 1998). An immediate FDA approval (1998) made Tamoxifen the first drug to prevent 23 
breast cancer.  24 
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The WFEB had by then a legendary reputation, specifically with respect to the role of ‘female 1 
hormones’, with the development of the first contraceptive pill (1955), and for pioneering 2 
animal in vitro fertilization (1959) (Pederson, 2011: 11). By 1971 the National Cancer Act 3 
secured the WFEB with an important grant for cancer research, and Edward Jensen was 4 
appointed as member of the Scientific Advisory Board. Having Jensen in the institution 5 
facilitated Jordan’s development of ICI-46,474 into a cancer drug, as Jensen trained Jordan in 6 
the (DMBA)-induced rat mammary carcinoma model and the technique to measure ER in 7 
animal and human tumours (Jordan and Brodie, 2007). The engagement of the 8 
pharmaceutical industry was also crucial in the conversion of Tamoxifen into a cancer drug. 9 
ICI bought a US pharmaceutical company which became ICI Americas and “provided human 10 
breast cancers for me [Jordan] to establish that tamoxifen blocked, the binding of estradiol to 11 
the ER” (Jordan and Brodie, 2007: 9). At the same time, the company recruited Jordan as 12 
scientific consultant, “to advocate tamoxifen to clinical trials groups (ECOG and the NSABP) 13 
for clinical testing” (Jordan, 2014: R240), the latter trial will boost Tamoxifen to stardom in 14 
the 1990s.  15 
Aromatase inhibitors (AIs). Like Tamoxifen, AIs started off as contraceptive drugs and their 16 
potential use as an anti-cancer drug was also developed at the WFEB. Experimental studies in 17 
animals began in the mid-1970s, and by 1979 one such compound was ready to be tested in 18 
the clinic. Yet as Angela Brodie, the lead researcher expressed, “Tamoxifen had by then been 19 
shown to be effective and there was a lack of enthusiasm to investigate other approaches, not 20 
only at the University of Maryland but also in pharmaceutical companies” (Jordan and 21 
Brodie, 2007: 4). AIs work by blocking the conversion, done by the enzyme aromatase, of 22 
androgens to oestrogen in body fat, liver, muscles and breast tumours. As such they are anti-23 
oestrogens, alongside Tamoxifen, both targeting different sites and mechanisms − ER action 24 
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(Tamoxifen) and oestrogen synthesis (AIs) − and under the same hypothesis of oestrogen-1 
dependence underlying cancer growth.   2 
The AI Formestane was available in 1993, becoming the second breast cancer drug. It was 3 
developed for postmenopausal women with ER+ and also for those women whose disease 4 
progressed under Tamoxifen. It is worth considering that the principle of aromatisation and of 5 
a drug that blocked this process was already existent in testolactone “an altered androgen 6 
molecule”, trialled first by the CBCG, whose aromatase inhibiting effects were later 7 
confirmed in the 1970s. The Brodie’s team focused instead on a “non-steroidal” compound 8 
with selective action, whereby the drug had no effect over adrenal hormone synthesis. The 9 
reception of AIs was subsequently hailed as superior to testolactone precisely for not 10 
producing “androgenic effects” (Geisler and Lønning, 2005).   11 
Hormone receptors: Alternative hypotheses  12 
New hypotheses emerged within the discipline of molecular biology and focused on the 13 
mechanisms and actions of hormone receptors and their genetic transcription - the ability to 14 
regulate gene expression through complex mechanisms which caused uncontrolled cell 15 
division and tumours to grow. Stemming from Jensen’s research on nuclear receptors and his 16 
novel perspective on tissue-action instead of hormone-action, these alternative hypotheses 17 
rendered new approaches to the then dominant presence of oestrogen and its receptor. 18 
Attention to their long-term development, as seen through a review of the literature, puts into 19 
perspective the struggles for legitimation within the HTF. The first results with Tamoxifen 20 
also guided this enquiry: in a clinical trial conducted in 1974 it was shown that 45% of 21 
women with ER+ did not respond to endocrine therapy (McGuire et al, 1977). Based on these 22 
unfavourable results, a group led by William McGuire and Kathryn Horwitz of the University 23 
of Texas, and Albert Segaloff (CBCG) proposed to investigate the action of other hormones 24 
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and their respective hormone receptors. The group first identified the progesterone hormone 1 
receptors (PgR) in mammary tumours and their role in predicting endocrine response for ER+ 2 
tumours. Their study stablished that the mere existence of ER+ did not indicate 3 
responsiveness to hormonal therapy. It was the evidence of hormone action that was needed. 4 
PgR, whose expression depends on the action of oestrogens, appeared as a marker of ER 5 
functionality, which ensured in turn responsiveness to endocrine therapies (Horwitz et al, 6 
1975).  7 
In another seminal study (Horwitz et al, 1975b), the action of hormone receptors of 8 
progesterone, prolactin, glucocorticoids, and androgens, as well as the mechanisms of inter-9 
hormonal control were studied in vitro. As the authors justified, “the mere presence of ER in 10 
a tumor does not guarantee that the tumor will behave in a hormone dependent fashion” 11 
(McGuire et al, 1977: 2936, my emphasis). ER behaviour was a term that brought instability 12 
and unpredictability to the dominant position of the oestrogen hypothesis. The biology of the 13 
mammary tumour thus presented by these researchers, emerged as a space of enormous 14 
physiological and chemical variations, whereby a series of hormones played a role, and in 15 
which oestrogens appeared only as one piece of the puzzle. However, as Bonnie Spanier has 16 
observed in her work on gender ideology in molecular biology, “gene expression” (or in this 17 
case ER expression) “increasingly become crystalized into “things”, rather than fleshed out as 18 
complex processes” (1995: 93). In the following subheadings, I present the different research 19 
lines that emerged from attention to these complex processes in tumour biology and how 20 
scientist themselves often expressed the constrains of the ER expression (rather than 21 
function) as dominant, centralised and hierarchical.   22 
Progesterone and its receptors: Research on progesterone receptors continued, and found a 23 
place in the clinic, but only as a biomarker of the functionality of ER+ and its potential 24 
response to hormonal treatment: double-positive tumours (ER+ and PgR+) respond better to 25 
17 
 
Tamoxifen. In relation to the action of progesterone and its receptors, research developments 1 
were less auspicious. In the 1990s one of the leading researchers, Horwitz, asked somewhat 2 
rhetorically: “But are estrogens the only hormones with a proliferative impact on the breast 3 
and on breast cancers?” (Horwitz, 1993: 211). The action of progesterone and progestins in 4 
cancer growth rendered some contradictory results as both stimulating and inhibiting tumour 5 
growth in animal models and cell lines between mid-1980s and early 1990s (Dao et al, 1982; 6 
Horwitz and Freidenberg,1985; Kordon et al, 1990; Lanari et al, 1986). Clinical research 7 
with high doses of progestins resulted in similar response rates to the one achieved by 8 
Tamoxifen (30%) (Sedlacek, 1988), and found a place in the clinic in the 1980s as a second-9 
line treatment after disease recurrence with Tamoxifen. But the arrival of AIs to the market 10 
heralded the demise of progestins as treatment.     11 
The anti-proliferative action of anti-progestins to inhibit tumour growth were also studied 12 
(Bakker et al, 1987; Bardon et al, 1985; Michna et al, 1992). Yet differences in the cell lines 13 
used, lab techniques, conditions for cell growth as well as action of different PgR isoforms 14 
have been acknowledged as part of the discrepancies regarding its potential action. Clinical 15 
research, however, compared to that observed with anti-oestrogens, was very sparse, and 16 
above all, slow: 12 years elapsed from the identification of PgR to the first clinical trial with 17 
an anti-progestin to treat breast cancer, whilst patient recruitment for the first two trials were 18 
considerably low (22 [Maudelonde et al, 1987] and 11 [Bakker et al, 1990] respectively. For 19 
ethical reasons, these small trials were conducted on postmenopausal women with metastatic 20 
cancer, after conventional therapy (surgery, radiotherapy, and Tamoxifen) had failed. Yet 21 
ethics, we can argue, does not explain the clear lack of support for clinical trials and low 22 
patient recruitment, which certainly contrasts with those included in the large clinical trials of 23 
Tamoxifen (40 RCT by 1992, involving 30,000 patients [Darby et al, 2005]). The underlying 24 
reason can be found in the drug itself: the anti-progestin RU 486, although scientifically 25 
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promising as an anti-cancer agent, was primarily considered an abortive drug, and in the US, 1 
the FDA banned its commercial use until the year 2000. Here, a combination of political 2 
(anti-abortion groups and politicians) and lack of a foreseeable profit from the pharmaceutical 3 
industry that sought no approval, among other actors (Clarke and Montini, 1993), were 4 
affecting other medical research areas such as cancer therapeutics. “Where do we begin?” 5 
Horwitz asked herself, and countered, “Ensuring that scientists and clinicians have access to 6 
antiprogestins, unencumbered by the Byzantine bureaucratic obstacles and the ‘antagonistic’ 7 
political climate currently encountered in the United States, is a good place to start” (Horwitz, 8 
1993: 224). The conclusions of the Institute of Medicine’s committee on the clinical uses of 9 
anti-progestins for breast cancer were rather demanding in requesting certainty in relation to 10 
the specific action of anti-progestins in a way that the anti-oestrogen (Tamoxifen) would have 11 
also struggled to offer at the time, i.e. in relation to Tamoxifen resistance and lack of 12 
knowledge in its mechanisms of action. The Institute recommended future clinical trials with 13 
antiprogestins, but it also warned, “Even if the clinical experience with antiprogestins 14 
demonstrates substantial activity with an acceptable toxicity profile, it will still be important 15 
to define a unique mechanism or role for the use of antiprogestins as compared to other 16 
available endocrine therapies” (Institute of Medicine,1993:47). 17 
Androgens and its receptors: The lack of therapeutic response of tumours classified as ER+ 18 
also stimulated experimental research into androgen responsiveness in different human breast 19 
cancer cell lines, which advanced the following findings: the clear existence of androgen-20 
responsive tumours, and therefore the usefulness in identifying androgen receptors (AR) – i.e. 21 
tumour cells that grow when androgens are administered, or that are inhibited after an anti-22 
androgen –, and the co-existence of ER and AR in the same cell line (Lippman et al, 1976). 23 
These researchers argued that although the role of androgens in breast cancer was 24 
determined, the key problem for its study resided in the limitations of the experimental 25 
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models available, i.e. the absence of cell lines that only expressed AR. This important 1 
limitation was also recently recognised by Coss et al (2014) and Taurilli et al (2014).  2 
As studies of ER (and later associated with the expression of PgR) became differentiated in 3 
predictive value (likely to respond to hormonal treatment) and prognostic factor (irrespective 4 
of treatment, tumours with a particular receptor will have better/worst outcomes), the ER 5 
assay for the determination of ER status was recommended by NIH consensus conference in 6 
1979 (Anon, 1979).  The AR predictive and prognostic value, however, has yet to have a 7 
defined role in the clinic, although they have long been researched (Agoff et al, 2003; Bryan 8 
et al, 1984; Engelsman et al, 1974; Isola, 1993; Moinfar et al, 2003; Søreide et al, 1992). 9 
Improving assay techniques to measure the presence of AR also helped expose other relevant 10 
factors, primarily, the high occurrence of AR in breast cancer tumours relative to the other 11 
two hormones: A study from Norway found that AR “was the sex hormone receptor most 12 
frequently found both in primary and secondary breast cancer”  ̶  the data for primary tumours 13 
was AR (84.9%); ER (72.1%) and PgR (67.1%) (Lea et al, 1989: 7162).  14 
Regulation of gene expression by hormone receptors: Research in molecular genetics 15 
significantly transformed the understanding of endocrine disorders through work in hormone 16 
receptors structure and functions − i.e. regulation of gene expression. Molecular cloning of 17 
ER (Green et al, 1986) shed light on the genetic organisation of the receptor, providing a 18 
functional description of distinct ER action as several domains: the one that bound DNA, that 19 
bound hormone, and that activates target genes. Molecular cloning also led to the 20 
identification of a second ER isoform, ERβ, with the one discovered earlier renamed ERα 21 
(Kuiper et al, 1996). Both have different biological functions, thus adding to the complexities 22 
of oestrogen action (differential transcriptional activities) in specific tissues (Zhao et al, 23 
2008).  As feminist scientist Deboleena Roy working at the time recalls, “the stable unitary 24 
identity of the estrogen receptor was displaced” causing “a minor endocrinological skirmish 25 
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in its day” (2018: 8-9).  In addition, O’Malley’s team identified new types of molecules 1 
named nuclear receptor “coactivators” and “corepressors” that were required for the 2 
functioning of hormone receptors and gene regulation (Baniahmad et al,1995; Smith et al, 3 
1997); and studies also demonstrated that ER nuclear activity was also regulated by 4 
epidermal growth factor and insulin-like growth factor type I (Nicholson et al, 1999). 5 
Finally, the identification of an oestrogen-binding site (G-protein-coupled receptor) in the 6 
cytoplasm and membranes of cells known as “non-nuclear” or “nongenomic”, that is, a new 7 
membrane-ER, showed to regulate too physiological responses (Filardo et al, 2000; Levin et 8 
al, 2001). Interestingly, some scientists promptly argued against the ER-focus in the clinic by 9 
stating, “we can no longer view ER for diagnostic and therapeutic purposes as a simple 10 
nuclear transcription factor. The standard for assessing tumor ER status is a simple 11 
immunohistochemistry assay detecting nuclear ER. This may need to be challenged” (Schiff 12 
et al, 2004: n/p). Renamed G- protein oestrogen receptor (GPER) in 2007 (Prossnitz and 13 
Arterburn, 2015), this new receptor was found to be expressed in 50% of breast cancers, 14 
indicating poor prognosis in high levels of expression, as well as in patients treated with 15 
Tamoxifen an increased risk of endometrial cancers, although a cancer-promoting role has 16 
not yet been elucidated (Prossnitz and Barton, 2011).        17 
Complex mechanisms were also advanced in relation to the other steroid hormones and its 18 
receptors. The progesterone receptor isoforms A & B discovered in the 1980s, returned 19 
evidence of differential mechanism of actions in breast tumours (Graham et al, 1995), ligand-20 
independent actions (Jacobsen et al, 2002), as well as complex-cross talk with ER (Kraus et 21 
al, 1995) and growth factor receptors (Pierson-Mullany et al, 2003), though as some scientists 22 
have argued, “the clinical significance of PR isoforms is likely vastly under-appreciated” 23 
(Hagan and Lange, 2014: 6). In the case of AR, studies from Australia reported that isoforms 24 
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may be involved not only in tumour growth/inhibition, but also in responsiveness to 1 
endocrine therapies (Birrel et al, 1998; Hall et al, 1996). 2 
By the year 2000, it seemed like the oestrogen hypothesis in the HTF has been sufficiently 3 
complicated, expanded or transcended in the work of many scientific groups though not in 4 
clinical ones, where ER assays and anti-oestrogen drugs reigned. A new classification (called 5 
“molecular portraits”) of tumours based on cell-type and molecular profile, and their 6 
predictive and prognostic value has proved that the oestrogen-driven clinical orientation was 7 
not just normalizing breast cancer intelligibility, but prescribing action (clinical 8 
management).  According to this classification, three gene expressions of receptors (ER, PgR 9 
HER2/neu), were involved in four distinct malignant subtypes: luminal A and luminal B, 10 
human epidermal growth factor receptor 2 (HER2)-enriched, and basal-like cancers (Perou, et 11 
al, 2000; Sørlie et al, 2001). The hormone receptor positive subtypes, luminal A (ER+ PG+) 12 
have the best prognosis and alongside luminal B subtype (ER+Pg+and HER2+) account for 13 
70% of breast cancers. The hormone-receptor negative subtypes are considered as presenting 14 
a more aggressive disease pattern and worse prognosis, HER2+ account for 20% of cancers, 15 
and the basal-like – also labelled “triple negative” for the lack of expression of ER, PG, 16 
HER2 – constitute the remaining 10% (Fioretti et al, 2014; Ross et al, 2009). Clearly, the 17 
“molecular portrait” did not incorporate AR gene expression profiling. So, which hormones 18 
made it to this classification? And what was “excluded”? It could be summarised by saying 19 
that, either a woman has a breast cancer with ER or lacks a “hormone-sensitive cancer”. 20 
Given that HER2 (Human Epidermal Growth Factor Receptor 2) is not a hormone, and that 21 
PgR is only assessed as a biomarker of ER functionality, the value assigned to the 22 
“expression” of ER seems the only voice that orients endocrine treatment. Tumours 23 
expressing HER2 are usually known as “hormone receptor negative”, meaning that they do 24 
not express ER+ or PgR+. Yet, by virtue of not being tested for AR, their hormonal status is 25 
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in fact, misleading: if they were routinely tested for AR, clinical researchers would frequently 1 
find that both AR and HER2 are expressed (Higa and Fell, 2013; Niemeier et al, 2010). The 2 
“molecular portraits” with a centralised control of ER thus seems a good example of what 3 
feminist anthropologist Emily Martin called “fitting an interpretation into the facts”, in 4 
relation to Western’s physiology preferences for explanatory models with hierarchical 5 
control. “Why not [she questions] instead of an organization with a controller, a team playing 6 
a game? (Martin, [1988] 2016: 272). 7 
New perspectives on androgens 8 
From around 2010, attention to the role of AR expression has visibly increased and attempted 9 
to re-enter the clinic through a focus on tumours (such as “triple negatives”) that did not fall 10 
into the recognised categories ER, PgR, HER2, as well as for cases where tumour resistance 11 
to hormone therapy drugs had occurred (Garay and Park, 2012). Part of this resurgence 12 
steamed from discourses on “personalised medicine”, and a conception of breast cancer as 13 
caused by complex mechanisms and interactions for which different targeted molecular 14 
therapies should be individually used at specific stages of the disease. 15 
A growing body of molecular and genomic studies about the role of AR in breast cancer 16 
tumours have provided a rationale for this renewed interest: firstly, the complex interactions 17 
or “cross-talk” between ERα and AR signalling pathways have put forward different 18 
propositions: that AR operated a “direct inhibition of ERα activity” (Peters, et al, 2009: 6131; 19 
6139); and that their interactions explained resistance to Tamoxifen (De Amicis et al, 2010; 20 
Sikora, 2016). Secondly, the relevance of AR as a prognostic marker, where a meta-analysis 21 
concluded that in early breast cancer, “Expression of AR in women with breast cancer is 22 
associated with better OS [overall survival] and DFS [disease-free survival] irrespective of 23 
coexpression of ER” (Vera-Badillo et al, 2014:1). 24 
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Clinical trials with AR antagonists (to block the receptor) have tested drugs used for the 1 
treatment of prostate cancer in AR+ triple negative tumours (Rampurwala et al, 2016). At the 2 
same time, other clinical trials are today testing a Selective Androgen Receptor Modulator 3 
(SARM), an AR agonist that activates the receptor in women with AR+ and triple negative 4 
(NCT02971761) and AR+ER+ tumours (Cancer Research UK, CRUK/15/075). As in 5 
previous decades, fear of ‘virilisation’ still seems to haunt scientists and it well deserves a 6 
note of reassurance from trialists: “[SARMs] are a new class of drugs under development for 7 
a variety of diseases due to their high specificity for AR, selective anabolic activity, lack of 8 
virilizing side effect, and ability to extend androgen therapy to women” (Narayanan et al, 9 
2014: 2). 10 
Finally, highlighting both the shortcomings of an ER only clinical focus and the evidence 11 
amassed in the past 60 years, some studies are proposing to tackle the interaction of the ER, 12 
PgR, AR, and other steroid hormones as a “family” and to treat them with “group therapy” 13 
(Sikora, 2016); whilst others propose to consider the “hormonal environments” (ER, PgR, 14 
AR) with a focus on the mammary gland developmental stages as it could improve, in the 15 
clinical setting, the appropriate AR targeting drugs as inhibitors or activators of androgen 16 
action (Tarulli et al, 2014: T189, T196).  17 
Discussion and Conclusions 18 
The literature examined for the period 1960-2016 on hormones and breast cancer has 19 
identified five main scientific hypotheses, research lines and therapeutic uses within the 20 
hormone therapy field (HTF). Drawing on Bourdieu’s scientific field analysis, from the 21 
findings I conclude that the already existing “oestrogen hypothesis” was further legitimised 22 
after the identification of the ER, which became the leading explanatory framework for the 23 
aetiology, diagnosis and treatment of breast cancer. I identify this continuity as scientific 24 
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habitus “which make possible the choice of objects, the solution of problems, and the 1 
evaluation of solutions” (Bourdieu, 1975: 30). In what Jensen emphasised as an “alternative 2 
approach” to the mechanism of oestrogen action (through the ER), it is possible to see the 3 
recurring value of the association oestrogens-breast cancer, operating at both levels of the 4 
HTF: the “internal”, where the struggle for specific capital is grounded in the oestrogen 5 
hypothesis as a legitimate constituent; and the “external”, where the influence of the social 6 
order is largely conceived and defined by questions of gender. Against this backdrop, the 7 
discovery of ER sounds less revolutionary, as it can be seen as tweaking objects of 8 
observation, facilitated by new available techniques (radioactive tracer) and above all, as 9 
ratifying legitimised questions: i.e. the oestrogen hypothesis and its enduring causal role in 10 
breast cancer since surgeon George Beatson in 1896 observed that by removing the ovaries 11 
(the main source of oestrogen production) it improved the clinical condition of women with 12 
breast cancer.   13 
The research identified as “androgens in the clinic”, offered by the CBCG, revealed a much 14 
more complicated use of therapeutic agents and exposed the underlying gender notions that 15 
permeated at the time, the social order. The clear effort by the CBCG to evaluate drug 16 
efficacy through “objective” improvements over “subjective” and “masculinizing action” 17 
gave androgens a potential role in the clinic. However, new androgens (with less 18 
androgenicity) had to work harder than oestrogens to find a place in the hormonal therapeutic 19 
armamentarium. The evidence-based data accumulated in these studies, which confirmed that 20 
androgens had a similar effect to oestrogen in remission rates and appeared to have not 21 
surpassed the subjective perception (social order- gender notions) of clinicians about their 22 
masculinising effects. The administration of androgens questioned the binary of two sexes 23 
and it proved an overdetermining factor in the abandonment of androgens in the clinical 24 
context, although not in the scientific one. It is possible to extend these contentions to the 25 
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assessment of testosterone in women’s athletics today and the controversial regulations of 1 
international committees banning women athletes with high testosterone levels. Feminists 2 
scholars have drawn attention to both the pervasiveness of testosterone with the 3 
male/masculine body, to the extent that endogenous and exogenous androgens in women 4 
become a “provocation/disruption” (Irni, 2016) or a “foreign substance” (Karkazis and 5 
Jordan-Young, 2018); and the obstinacy of committees in disregarding scientific evidence.  6 
The third research line, “tackling oestrogen action and synthesis” led to a stellar reception of 7 
drugs (Tamoxifen and aromatase inhibitors) in clinical research and practice. This therapeutic 8 
success within HTF can be interpreted as both scientific habitus (as an object of study, as a 9 
problem and as therapeutic solutions), overdetermined by a clear gendered articulation that 10 
supported the persistence of the oestrogen hypothesis: that the female ‘sex hormone’ par 11 
excellence (oestrogen) can cause cancer and this can be controlled and prevented by agents 12 
that block its action (anti-oestrogen) or inhibit its synthesis (aromatase inhibitors). The 13 
scientific “investment” as Bourdieu puts it, whereby the:  14 
researchers’ tendency to concentrate on those problems regarded as the most 15 
important ones (e.g. because they have been constituted as such by producers 16 
endowed with a high degree of legitimacy) is explained by the fact that a 17 
contribution or discovery relating to those questions will tend to yield greater 18 
symbolic profit. (1975: 22).  19 
From a clinical point of view, it certainly did, as prescribing Tamoxifen is largely common 20 
sense. Although the effectiveness of the drug in reducing the risk of recurrence by about a 21 
half and mortality by about a third have been proven (EBCTCG, 2005), there is still one-third 22 
of women with ER+ tumours that will develop drug resistance and mortality, and another 23 
third of tumours that are not ER+. This is not about seeing the glass half-empty. It is more 24 
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about offering an explanation as to why the oestrogen hypothesis still dominates in the clinic 1 
despite 40 years of attempts to understand breast cancer as “a constantly evolving, moving 2 
target” (Carroll, 2016: R42). 3 
Therefore, there are two instances where Bourdieu’s field analysis can shed some light for the 4 
HTF, the first one is the one already discussed in relation to the internal and external forces 5 
operating in the field which questions its “autonomy”. In this sense, the degree of legitimacy 6 
of the oestrogen hypothesis does not operate in the “internal”, intrinsic world of institutions 7 
(e.g. Worcester Foundation), and scientists (Jensen, Jordan, Brodie). “In fields with weak 8 
autonomy, which are therefore deeply immersed in social relations” says Bourdieu, “external 9 
pressure” i.e. resistance from political, religious or economic forces prevails (Bourdieu, 2004: 10 
87). The HTF, like any area of research producing highly profitable products (drugs and 11 
tests), appears as particularly exposed to heteronomy. On the one hand, the pharmaceutical 12 
industry has been an active player in the marketing of ‘sex hormones’ since their isolation in 13 
the 1930s. Oestrogens, in particular, have been prescribed for a range of gynaecological 14 
disorders, contraception, menopause and osteoporosis, developing a well-known history of 15 
profit-oriented performance whilst driving sex/gender specificity in disease patterns and 16 
treatment consumption (Fausto-Sterling, 2005; Krieger, et al, 2005; Marks, 2010; Oudshoorn 17 
1994; Roberts, 2007; Watkins, 2007). On the other, the accumulation of capital in the HTF is, 18 
as I have argued, better understood by the interactions with the “external”, social 19 
order/gender values, or to paraphrase Moi’s reading of Bourdieu (1999) by conceding that 20 
gender is better understood as part of the field. This has been exemplified by “androgens in 21 
the clinic” where the mobilisation of pervasive cultural understandings of sex differences 22 
returned to the HTF an enduring struggle. This relates to the second instance of Bourdieu’s 23 
field analysis, the scientific struggle for legitimacy, which he exemplified through the 24 
“conservation” or “succession” strategies, i.e. those scientists that embrace the dominant 25 
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approaches and thus secure a career of prestige through “limited innovations”; and those who 1 
attempt to transform the existing order and invest in new, challenging  theories, but whose 2 
legitimacy and impact will be much restricted (Bourdieu, 1975; 1991). In the HTF, 3 
legitimation depends on the clinical context, where on the one hand, patients either improve, 4 
survive, or confirm the efficacy of new drugs and tests, and on the other, hormonal treatments 5 
need to conform with the wider models of the male and female body, therefore struggles and 6 
competition for scientific legitimacy appear to be less polarised. In this sense, while there is a 7 
clear identification of those scientists working within the dominant, legitimated area of the 8 
oestrogen hypothesis, those seeking transformation did so with a tacit acceptance of the rules 9 
of the game, intrinsic to the field.  I would argue that the “alternative hypotheses” that 10 
emerged in the 1970s (i.e. research into the role of progesterone and androgens) started off 11 
not as a rupture or opposition with the older order (ER action), but by permanently 12 
questioning its many shortcomings as a single explanatory theory. Through engagement with 13 
ER, these researchers opened up innovation in areas of research which led to modest, 14 
incremental additions, but certain in the assertion that ER was no more than one of the many 15 
mechanisms. Notably, they have enjoyed moderate scientific recognition but have failed to 16 
gain legitimation in the clinic: ER assays and oncogene analysis feature in breast cancer 17 
therapeutic orientation, but both PgR and AR are still struggling to find an independent role 18 
(i.e. prognostic value and treatment). One aspect that these new hypotheses remarkably 19 
contributed was the notion of ‘tumour behaviour’: the consideration of ER status, as an 20 
instance in time, not a fixed trait or entity. As feminist biologist Anne Fausto-Sterling has 21 
argued, “Believing that traits are static creates methodological conundrums” (2017:65) and 22 
this has been particularly problematic in the clinical management of breast cancer − ER+ loss 23 
of status and gene mutation leading to intrinsic and acquired resistance to hormone therapies, 24 
and discordance of receptor status between primary and recurrent tumours.  25 
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The most recent research identified in the HTF, the “new perspectives on androgens”, with 1 
the ongoing clinical trials with anti-androgens and SARMs point toward the AR role as a 2 
potential therapeutic target. Yet concern about virilisation is very present and recent 3 
formulations often refer to past undesirable side effects as a flaw, thus, still perpetuating the 4 
same contention. Although the social order where these latest developments and trials have 5 
emerged are embedded in a fast-changing and complex gender landscape − where gender 6 
fluidity, non-binary thinking, intersex and trans activism have broken the mould of the 7 
traditional binary system – however, caution is warranted. Whilst current scientific 8 
perspectives draw attention to the breast cancer tumour’s “hormonal environment” and the 9 
“hormone receptor family” to redirect the focus outside the determinism of oestrogens, 10 
opening up (again) the possibility to decouple sex from hormones, other closely related fields 11 
such as clinical/applied medicine and the pharmaceutical/ genomics industry can still offer 12 
renewed resistance. For example, the growing body of literature, services and research 13 
centres on gender-specific medicine, which reifies sex-based difference, promotes, as 14 
Annandale and Hammarström have argued, a “vision of the biological body as binary and 15 
determinate” (2010: 583). In addition, a novel test (Oncotype DX) has recently been endorsed 16 
by international clinical guidelines for the routine management of ER+ tumours only − a gene 17 
expression testing to predict risk of recurrence and to help oncologists in deciding on whether 18 
to prescribe chemotherapy − has been positively received by health systems and specialists 19 
alike. As the oestrogen receptors enter the muddle arena of “technological expectations”, the 20 
dominant position of oestrogens and its receptors in the clinic may well be unaffected. 21 
i On oestrogen action: Allen and Doisy 1923 administered oestrogens to ovariectomised rats 
obtaining the cornification of the vagina; whilst Lacassagne 1932, observed that oestrogen 
injections increased the incidence of breast cancer in female and male mice.   
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